NO20084665L - Quinazoliner for PDK1-inhibering - Google Patents

Quinazoliner for PDK1-inhibering

Info

Publication number
NO20084665L
NO20084665L NO20084665A NO20084665A NO20084665L NO 20084665 L NO20084665 L NO 20084665L NO 20084665 A NO20084665 A NO 20084665A NO 20084665 A NO20084665 A NO 20084665A NO 20084665 L NO20084665 L NO 20084665L
Authority
NO
Norway
Prior art keywords
quinazolines
pdk1 inhibition
pdk1
inhibition
Prior art date
Application number
NO20084665A
Other languages
English (en)
Inventor
Savithri Ramurthy
Xiadong Lin
Sharada Subramanian
Alice C Rico
Xiajong M Wang
Rama Jain
Jeremy M Murray
Steven E Basman
Robert L Warne
Wei Shu
Yasheen Zhou
Jeffrey Dove
Mina Aikawa
Payman Amiri
Weibo Wang
Johanna M Jansen
Allan S Wagman
Keith B Pfister
Simon C Ng
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20084665L publication Critical patent/NO20084665L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20084665A 2006-04-06 2008-11-05 Quinazoliner for PDK1-inhibering NO20084665L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79030406P 2006-04-06 2006-04-06
PCT/US2007/008592 WO2007117607A2 (en) 2006-04-06 2007-04-05 Quinazolines for pdk1 inhibition

Publications (1)

Publication Number Publication Date
NO20084665L true NO20084665L (no) 2009-01-06

Family

ID=38476139

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084665A NO20084665L (no) 2006-04-06 2008-11-05 Quinazoliner for PDK1-inhibering

Country Status (22)

Country Link
US (1) US7932262B2 (no)
EP (1) EP2004615A2 (no)
JP (1) JP2009532486A (no)
KR (1) KR20080111114A (no)
CN (1) CN101454294A (no)
AR (1) AR060358A1 (no)
AU (1) AU2007235339A1 (no)
BR (1) BRPI0710521A2 (no)
CA (1) CA2648529A1 (no)
CR (1) CR10427A (no)
EA (1) EA200870415A1 (no)
EC (1) ECSP088823A (no)
GT (1) GT200800202A (no)
MA (1) MA30358B1 (no)
MX (1) MX2008012852A (no)
NO (1) NO20084665L (no)
PE (1) PE20080059A1 (no)
SM (1) SMP200800059B (no)
TN (1) TNSN08375A1 (no)
TW (1) TW200808739A (no)
WO (1) WO2007117607A2 (no)
ZA (1) ZA200808307B (no)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009006627A (es) * 2006-12-22 2009-08-12 Novartis Ag Quinazolinas para la inhibicion de pdk1.
UY31137A1 (es) * 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
WO2009007984A2 (en) * 2007-07-11 2009-01-15 Hetero Drugs Limited An improved process for erlotinib hydrochloride
EP2226315A4 (en) 2007-12-28 2012-01-25 Carna Biosciences Inc 2-AMINOQUINAZOLINE DERIVATIVE
US7923450B2 (en) * 2008-01-11 2011-04-12 Hoffmann-La Roche Inc. Modulators for amyloid beta
EP2269993B1 (en) 2008-04-23 2013-02-27 Kyowa Hakko Kirin Co., Ltd. 2-aminoquinazoline derivative
AU2009248774B2 (en) 2008-05-23 2012-05-31 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
EP2307400B1 (en) * 2008-05-30 2014-04-23 Amgen, Inc Inhibitors of pi3 kinase
US20100121052A1 (en) * 2008-06-20 2010-05-13 Rama Jain Novel compounds for treating proliferative diseases
EP2381943A1 (en) * 2008-12-29 2011-11-02 Fovea Pharmaceuticals Substituted quinazoline compounds
WO2012044090A2 (ko) * 2010-09-29 2012-04-05 크리스탈지노믹스(주) 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물
WO2013050527A1 (en) 2011-10-05 2013-04-11 H. Lundbeck A/S Quinazoline derivatives as pde10a enzyme inhibitors
KR101360948B1 (ko) * 2012-01-17 2014-02-12 한국과학기술연구원 신규한 2-아미노퀴나졸린 유도체 및 이를 유효성분으로 포함하는 항암제
GB201216017D0 (en) * 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
RU2718876C2 (ru) * 2013-08-23 2020-04-15 Ньюфарма, Инк. Некоторые химические соединения, композиции и способы
WO2015083833A1 (ja) * 2013-12-06 2015-06-11 カルナバイオサイエンス株式会社 新規キナゾリン誘導体
CN105814022B (zh) * 2013-12-09 2018-09-28 Ucb生物制药私人有限公司 作为tnf活性调节剂的稠合的二环杂芳族衍生物
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
HUE053654T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
US10047037B2 (en) 2014-09-01 2018-08-14 Nippon Soda Co., Ltd. Method for producing 2-amino-substituted benzaldehyde compound
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
JP6385584B2 (ja) 2014-12-24 2018-09-05 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のための縮合ピリミジン化合物
MX2017008518A (es) 2014-12-24 2017-10-25 Gilead Sciences Inc Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
WO2016133935A1 (en) * 2015-02-17 2016-08-25 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN113999180B (zh) * 2015-07-03 2024-03-26 上海医药集团股份有限公司 喹唑啉类化合物、其中间体、制备方法、药物组合物和应用
CN106366093B (zh) * 2015-07-21 2020-08-18 广州再极医药科技有限公司 稠环嘧啶类化合物、中间体、其制备方法、组合物和应用
EP3356348B1 (en) * 2015-10-02 2021-05-05 Sentinel Oncology Limited 2-aminoquinazoline derivatives as p70s6 kinase inhibitors
CN105753793B (zh) * 2016-01-19 2018-09-04 河北医科大学 芳甲酰脲偶联喹唑啉类化合物及其制备方法、药物组合物及药物用途
EP3497087B1 (en) 2016-08-15 2021-11-10 Neupharma, Inc. Pyrrolo[1,2-c]pyrimidine, imidazo[1,5-c]pyrimidine, quinazoline, purine and imidazo[1,5-a][1,3,5]triazine derivatives as tyrosine kinase inhibitors for the treatment of cancer
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
RU2761824C2 (ru) 2018-08-03 2021-12-13 Закрытое Акционерное Общество "Биокад" Ингибиторы CDK8/19
CN110872243B (zh) * 2018-08-31 2023-03-31 四川科伦博泰生物医药股份有限公司 磺酰胺类化合物、其制备方法及用途
CN109320511A (zh) * 2018-10-26 2019-02-12 广安凯特制药有限公司 一种高纯度帕博西尼中间体产品及其制备方法
US11820837B2 (en) * 2019-06-05 2023-11-21 Advanced Technologies For Novel Therapeutics, Llc Modified peptides and associated methods of use
CN113384582A (zh) * 2020-03-13 2021-09-14 广州再极医药科技有限公司 稠环嘧啶化合物在制备治疗癌症的药物中的应用
CN114315798A (zh) * 2020-09-29 2022-04-12 深圳智药信息科技有限公司 喹唑啉类化合物及其药物组合物
US20230406864A1 (en) * 2020-11-09 2023-12-21 Merck Sharp & Dohme Llc 7-azole substituted 2-aminoquinazoline inhibitors of hpk1
US20230399341A1 (en) * 2020-11-09 2023-12-14 Merck Sharp & Dohme Llc 7-phenyl substituted 2-aminoquinazoline inhibitors of hpk1
CN117136190A (zh) * 2021-04-22 2023-11-28 浙江海正药业股份有限公司 芳香稠合环类衍生物及其制备方法和用途
CN114533733A (zh) * 2021-12-31 2022-05-27 北京鑫开元医药科技有限公司 一种异喹啉-1,3-二胺类似物药物制剂及其制备方法
CN113999206B (zh) * 2021-12-31 2022-04-12 北京鑫开元医药科技有限公司 异喹啉-1,3-二胺类似物、制备方法、药物组合物及其应用
WO2023138412A1 (en) * 2022-01-20 2023-07-27 Insilico Medicine Ip Limited Fused pyrimidin-2-amine compounds as cdk20 inhibitors
WO2023143135A1 (zh) * 2022-01-28 2023-08-03 赛诺哈勃药业（成都）有限公司 一种喹唑啉衍生物及其用途
CN116672450A (zh) * 2022-02-23 2023-09-01 智宠制药（北京）有限公司 Hpk1抑制剂在治疗干扰素相关疾病中的应用
WO2023218241A1 (en) * 2022-05-13 2023-11-16 Voronoi Inc. Heteroaryl derivative compounds, and pharmaceutical composition comprising thereof
WO2024020380A1 (en) * 2022-07-18 2024-01-25 Iambic Therapeutics, Inc. Quinazoline compounds and methods of use
WO2024131938A1 (zh) * 2022-12-23 2024-06-27 赛诺哈勃药业（成都）有限公司 喹唑啉类化合物及其用途
WO2024186579A1 (en) * 2023-03-03 2024-09-12 Deliver Therapeutics, Inc. Protein kinase inhibitors and uses thereof

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US134846A (en) 1873-01-14 Half his eight to william h
US73044A (en) 1868-01-07 John c
US171303A (en) 1875-12-21 Improvement in corn-stalk knives
JPS6041077B2 (ja) * 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US4323581A (en) * 1978-07-31 1982-04-06 Johnson & Johnson Method of treating carcinogenesis
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4923986A (en) 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
US4904768A (en) * 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
JP2766360B2 (ja) 1988-02-04 1998-06-18 協和醗酵工業株式会社 スタウロスポリン誘導体
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
WO1993007153A1 (en) 1991-10-10 1993-04-15 Schering Corporation 4'-(n-substituted-n-oxide)staurosporine derivatives
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
JPH07505124A (ja) 1991-11-08 1995-06-08 ザ ユニバーシティ オブ サザン カリフォルニア ニューロトロフィン活性増強のためのｋ−２５２化合物を含む組成物
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5948898A (en) 1992-03-16 1999-09-07 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5756494A (en) 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5621100A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
ES2225824T3 (es) 1992-08-31 2005-03-16 Ludwig Institute For Cancer Research Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos.
WO1994006799A1 (fr) 1992-09-21 1994-03-31 Kyowa Hakko Kogyo Co., Ltd. Remede contre la thrombopenie
DK0666868T4 (da) 1992-10-28 2006-09-18 Genentech Inc Anvendelse af anti-VEGF-antistoffer til behandling af cancer
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
EP0708772B1 (en) * 1993-07-15 2000-08-23 Minnesota Mining And Manufacturing Company IMIDAZO [4,5-c]PYRIDIN-4-AMINES
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
DK0817627T3 (da) 1993-12-23 2005-06-06 Lilly Co Eli Inhibitorer af proteinkinase C
US5525613A (en) * 1994-06-16 1996-06-11 Entropin, Inc. Covalently coupled benzoylecgonine ecgonine and ecgonidine
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5482936A (en) * 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
EP1110953B1 (en) 1995-03-30 2009-10-28 Pfizer Products Inc. Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US6331555B1 (en) * 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
WO1997007081A2 (en) 1995-08-11 1997-02-27 Yale University Glycosylated indolocarbazole synthesis
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
DE69620445T2 (de) 1995-12-08 2002-12-12 Janssen Pharmaceutica N.V., Beerse (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
KR100447918B1 (ko) * 1996-07-25 2005-09-28 동아제약주식회사 대장을포함한위장관보호작용을갖는플라본및플라바논화합물
EP0917569B1 (en) 1996-08-02 2005-11-09 GeneSense Technologies Inc. Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
DE69832715T2 (de) 1997-07-12 2007-01-11 Cancer Research Technology Ltd. Cyclin-abhängige-kinase inhibierende purinderivate
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
SK287132B6 (sk) 1998-05-29 2009-12-07 Sugen, Inc. Farmaceutická kompozícia obsahujúca pyrolom substituovaný 2-indolinón, súprava obsahujúca uvedenú kompozíciu a použitie pyrolom substituovaného 2-indolinónu
US20030083242A1 (en) 1998-11-06 2003-05-01 Alphonse Galdes Methods and compositions for treating or preventing peripheral neuropathies
IL146954A0 (en) 1999-06-25 2002-08-14 Genentech Inc HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
EP1201668A4 (en) 1999-07-13 2003-05-21 Kyowa Hakko Kogyo Kk STAUROSPORINE DERIVATIVES
PT1244647E (pt) 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
US6982260B1 (en) * 1999-11-22 2006-01-03 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
JP2003514901A (ja) 1999-11-22 2003-04-22 ワーナー−ランバート・カンパニー キナゾリン類およびシクリン依存性キナーゼ酵素を阻害するためのその使用
DE122010000004I1 (de) 2000-02-15 2010-04-15 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
CA2406847C (en) 2000-04-12 2009-11-17 Genaera Corporation Regioselective and stereoselective oxidation of fused ring systems useful for the preparation of aminosterols
CZ299561B6 (cs) 2000-06-30 2008-09-03 Glaxo Group Limited Chinazolinaminový derivát a farmaceutický prostredek
EP1317442B1 (en) * 2000-09-11 2005-11-16 Chiron Corporation Quinolinone derivatives as tyrosine kinase inhibitors
US6677450B2 (en) 2000-10-06 2004-01-13 Bristol-Myers Squibb Company Topoisomerase inhibitors
DE60211329T2 (de) 2001-01-16 2007-05-24 Regeneron Pharmaceuticals, Inc. Isolierung von sezernierte proteine exprimierenden zellen
WO2002062826A1 (fr) 2001-02-07 2002-08-15 Vadim Viktorovich Novikov Procede de fabrication des peptides
WO2003004505A1 (en) 2001-07-02 2003-01-16 Debiopharm S.A. Oxaliplatin active substance with a very low content of oxalic acid
KR100484504B1 (ko) 2001-09-18 2005-04-20 학교법인 포항공과대학교 쿠커비투릴 유도체를 주인 분자로서 포함하고 있는 내포화합물 및 이를 포함한 약제학적 조성물
US20030134846A1 (en) * 2001-10-09 2003-07-17 Schering Corporation Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
WO2003077902A1 (en) * 2002-02-19 2003-09-25 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
CA2480638C (en) 2002-03-29 2013-02-12 Chiron Corporation Substituted benzazoles and use thereof as raf kinase inhibitors
US6900342B2 (en) * 2002-05-10 2005-05-31 Dabur India Limited Anticancer taxanes such as paclitaxel, docetaxel and their structural analogs, and a method for the preparation thereof
US6727272B1 (en) 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2004060308A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
BRPI0406809A (pt) 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
WO2004064759A2 (en) 2003-01-21 2004-08-05 Chiron Corporation Use of tryptanthrin compounds for immune potentiation
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
CA2539549A1 (en) 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
MX2007003078A (es) 2004-09-14 2007-05-16 Novartis Vaccines & Diagnostic Compuestos de imidazoquinolina.
JP5079500B2 (ja) * 2005-04-28 2012-11-21 協和発酵キリン株式会社 ２−アミノキナゾリン誘導体
WO2006137421A1 (ja) * 2005-06-21 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. 局所投与剤
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use

Also Published As

Publication number Publication date
WO2007117607A3 (en) 2007-12-21
JP2009532486A (ja) 2009-09-10
TW200808739A (en) 2008-02-16
AR060358A1 (es) 2008-06-11
TNSN08375A1 (en) 2009-12-29
CA2648529A1 (en) 2007-10-18
KR20080111114A (ko) 2008-12-22
ECSP088823A (es) 2008-12-30
GT200800202A (es) 2009-06-25
MX2008012852A (es) 2008-11-28
PE20080059A1 (es) 2008-03-05
CR10427A (es) 2009-01-27
EA200870415A1 (ru) 2009-02-27
EP2004615A2 (en) 2008-12-24
WO2007117607A2 (en) 2007-10-18
WO2007117607A9 (en) 2008-03-06
BRPI0710521A2 (pt) 2012-03-13
MA30358B1 (fr) 2009-04-01
US7932262B2 (en) 2011-04-26
US20100048561A1 (en) 2010-02-25
CN101454294A (zh) 2009-06-10
AU2007235339A8 (en) 2008-11-20
ZA200808307B (en) 2010-01-27
SMAP200800059A (it) 2008-11-12
SMP200800059B (it) 2009-09-07
AU2007235339A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
CR10833A (es) Quinazolines for pdk1 inhibition
NO20084665L (no) Quinazoliner for PDK1-inhibering
CY2017016I1 (el) Αναστολεις πρωτεασωματος
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
DK2402317T3 (da) DGAT-inhibitor
DK2066662T3 (da) Serinhydrolaseinhibitorer
FI20065446A0 (fi) Muodostusosa
BRPI0911977A2 (pt) quinazolinas substituídas
BRPI0911967A2 (pt) quinazolinas substituídas
ATE522533T1 (de) Pyrazolopyrimidinonkinaseinhibitor
ATE524972T1 (de) Poly-tlr-antagonist
BRPI0912672A2 (pt) quinazolinas substituídas
BRPI0719883A2 (pt) Inibidores de quinase
DE102007046051B8 (de) Laibungsanschlussprofil
FI20065196A0 (fi) Muodostusosa
UA14866S (uk) Профіль для карниза
UA14869S (uk) Профіль для карниза
UA14868S (uk) Профіль для карниза
CN300885251S (zh) 盥洗盆
ITMN20060002U1 (it) Lavabo
UA13968S (uk) Профіль будівельний
UA14574S (uk) Профіль
UA14579S (uk) Профіль
UA13196S (uk) Профіль

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application